摘要
目的探讨依达拉奉联合尤瑞克林对进展性脑梗死患者的临床应用效果。方法选择我院收治的50例进展性脑梗死患者,随机分为对照组和观察组各25例,对照组予以常规综合治疗,观察组予以依达拉奉联合尤瑞克林治疗,观察两组患者的治疗效果和NIHSS评分。结果观察组患者的治疗有效率和NIHSS评分均优于对照组,P<0.05。结论依达拉奉联合尤瑞克林治疗进展性脑梗死,效果良好。
Objective To investigate the clinical effect of edaravone combined with urinary kalidinogenase on progressive cerebral infarction patients.MethodsIn our hospital,50 cases of progressive cerebral infarction patients were randomly assigned to control group and observation group,each group of 25 cases. The control group received routine comprehensive treatment,the observation group received edaravone and urinary kalidinogenase treatment,then observed two groups of patients of the treatment effect and the NIHSS score.Results Observation group of treatment effective rate and NIHSS scores were better than the control group,P〈0.05.Conclusion Edaravone combined with urinary kalidinogenase in treatment of progressive cerebral infarction has good effect.
出处
《中国卫生标准管理》
2016年第11期115-116,共2页
China Health Standard Management
关键词
依拉达奉
尤瑞克林
进展性脑梗死
Edaravone
Urinary kalidinogenase
Progressive cerebral infarction
